Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 2260 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
 

Table of Contents   
LETTER TO THE EDITOR  
Year : 2019  |  Volume : 30  |  Issue : 4  |  Page : 998-999
Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy


National Oncology Center, The Royal Hospital, Post Box 1331, Seeb, Postal Code 111, Muscat, Sultanate of Oman

Click here for correspondence address and email

Date of Submission23-Mar-2019
Date of Acceptance29-Apr-2019
Date of Web Publication27-Aug-2019
 

How to cite this article:
Venniyoor A. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy. Saudi J Kidney Dis Transpl 2019;30:998-9

How to cite this URL:
Venniyoor A. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy. Saudi J Kidney Dis Transpl [serial online] 2019 [cited 2019 Nov 18];30:998-9. Available from: http://www.sjkdt.org/text.asp?2019/30/4/998/265483


To the Editor,

The Guru et al[1] study (Saudi J Kidney Dis Transpl 2019;30(2):526-30) describes a case of progressive multifocal leukoencephalopathy (PML) occurring in a renal transplant patient who subsequently expired. They have listed the limited options available for treatment but note a uniformly fatal outcome with a median survival of 6.4 months. Cortese et al[2] article published in the New England Journal of Medicine reported a significant advance in treatment of this disease, with the use of immune checkpoint inhibitors (CPi) – pembro-lizumab and nivolumab. These drugs are Food and Drug Administration approved for immuno-therapy of multiple cancers. The interaction between Programmed cell death protein 1 (PD-1) (on the cytotoxic T-cells) and programmed death ligand 1 (PD-L1) (on the tumor cells) induce immune tolerance for the cancer cells; CPi block this interaction and invigorate the antitumor activity of T-cells. Three groups[2],[3],[4] reported the use of these drugs in treatment of PML arising in 10 patients of hematological disorders or HIV infection. Seven of them improved to varying degrees, and as the editorial notes,[5] the presence of JC virus-specific T-cells in the blood appears to be a prerequisite for their use, something not reported in this case. Other success stories have appeared in recent literature.[6] These series however did not include any organ transplant patients, and it would be interesting to see whether CPi work in this group without significant adverse events. CPi are relatively contraindicated in patients on steroids [such as those with autoimmune disorders and organ transplant, as steroids may (theoretically) prevent the immune stimulation] but have been used in transplant patients for treatment of malignancies, with both tumor regression and graft rejection[7]. Hence, the risk to benefit ratio must be carefully considered before using CPi for PML in transplant patients. Interestingly, CPi themselves are associated with PML.[8]

Conflict of interest: None declared.



 
   References Top

1.
Guru PK, Vissing MB, Agarwal A, Krishna M. Biopsy-proven progressive multifocal leukoencephalopathy in a renal transplant patient. Saudi J Kidney Dis Transpl 2019;30: 526-30.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 2019;380:1597-605.  Back to cited text no. 2
    
3.
Walter O, Treiner E, Bonneville F, et al. Treatment of progressive multifocal leuko- encephalopathy with nivolumab. N Engl J Med 2019;380:1674-6.  Back to cited text no. 3
    
4.
Rauer S, Marks R, Urbach H, et al. Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med 2019;380: 1676-7.  Back to cited text no. 4
    
5.
Koralnik IJ. Can immune checkpoint inhibitors keep JC virus in check? N Engl J Med 2019; 380:1667-8.  Back to cited text no. 5
    
6.
Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB. Progressive multifocal leuko-encephalopathy treated with nivolumab. J Neurovirol 2019;25:284-7.  Back to cited text no. 6
    
7.
De Bruyn P, Van Gestel D, Ost P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: How far can we go? Curr Opin Oncol 2019;31:54-64.  Back to cited text no. 7
    
8.
Martinot M, Ahle G, Petrosyan I, et al. Progressive multifocal leukoencephalopathy after treatment with nivolumab. Emerg Infect Dis 2018;24:1594-6.  Back to cited text no. 8
    

Top
Correspondence Address:
Ajit Venniyoor
National Oncology Center, The Royal Hospital, Post Box 1331, Seeb, Postal Code 111, Muscat
Sultanate of Oman
Login to access the Email id


DOI: 10.4103/1319-2442.265483

PMID: 31464264

Rights and Permissions




 

Top
   
 
 
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  
 


 
    References
 

 Article Access Statistics
    Viewed217    
    Printed0    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal